Commonwealth Equity Services
BBIO icon

Commonwealth Equity Services’s BridgeBio Pharma BBIO Stock Holding History

Commonwealth Equity Services’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$229K Sell
3,078
-2,015
-40% -$141K ﹤0.01% 4018
2026
Q1 		$378K Sell
5,093
-86
-2% -$6.23K ﹤0.01% 3460
2025
Q4 		$396K Buy
5,179
+244
+5% +$16K ﹤0.01% 3394
2025
Q3 		$256K Sell
4,935
-75
-1% -$3.66K ﹤0.01% 3766
2025
Q2 		$216K Buy
+5,010
New +$182K ﹤0.01% 3861

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Commonwealth Equity Services's BBIO Position: Q2 2026 in Review

Commonwealth Equity Services reduced its BridgeBio Pharma (BBIO) stake by 40% in Q2 2026, selling an estimated $141K and leaving 3,078 shares worth $229K. The position accounts for ﹤0.01% of the portfolio, ranked #4018.

Commonwealth Equity Services first reported a position in BBIO in Q2 2025 and has held it in 5 quarters since. The position peaked at $396K in Q4 2025. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • Commonwealth Equity Services held 3,078 shares of BridgeBio Pharma worth $229K as of Q2 2026.
  • Commonwealth Equity Services sold 2,015 BridgeBio Pharma shares in Q2 2026, an estimated $141K.
  • BridgeBio Pharma made up ﹤0.01% of Commonwealth Equity Services's portfolio in Q2 2026, its #4018 holding.
  • Commonwealth Equity Services first reported a position in BridgeBio Pharma in Q2 2025 and has held it in 5 quarters since.
  • Commonwealth Equity Services's BridgeBio Pharma position peaked at $396K in Q4 2025.
  • 474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Commonwealth Equity Services's 13F filing for Q2 2026, filed 29 Jul 2026.